+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Market Spotlight: Uterine Cancer

  • Report

  • 42 Pages
  • April 2021
  • Region: Global
  • Citeline
  • ID: 4462175
This Market Spotlight report covers the Uterine Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

  • The publisher estimates that in 2019, there were 385,200 incident cases of uterine cancer in females worldwide, and expects that number to increase to 404,300 incident cases by 2028.
  • In the same year, there were an estimated 1.3 million five-year prevalent cases of uterine cancer worldwide, which is expected to increase slightly to 1.4 million cases by 2028.
  • Merck & Co’s Keytruda and Eisai’s Lenvima are the only FDA-approved drugs for uterine cancer. These drugs are administered via the intravenous and oral routes, respectively.
  • The majority of industry-sponsored drugs in active clinical development for uterine cancer are in Phase II, with only one drug in the NDA/BLA stage.
  • Therapies in active clinical development for uterine cancer focus on a wide variety of targets. These drugs are administered via the oral and intravenous routes.
  • High-impact upcoming events for drugs in the uterine cancer space comprise topline Phase III trial results for Xpovio and dostarlimab, and a PDUFA date as well as an expected European approval decision for dostarlimab.
  • The overall likelihood of approval of a Phase I solid tumors asset is 5.3%, and the average probability a drug advances from Phase III is 42.8%. Drugs, on average, take 9.7 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
  • The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for uterine neoplasms have been in the early and mid-phases of development, with 95% of trials in Phase I–II, and only 5% in Phase III–IV.
  • The US has a substantial lead in the number of uterine neoplasms clinical trials globally. Spain leads the major European markets, while China and Thailand share the top spot in Asia.
  • Sanofi has the highest number of completed clinical trials for uterine neoplasms, with five trials.
  • AstraZeneca and Sanofi lead the industry sponsors with the highest overall number of clinical trials for uterine neoplasms.

Table of Contents

OVERVIEWKEY TAKEAWAYSDISEASE BACKGROUND
TREATMENT
  • Surgery
  • Radiation therapy
  • Chemotherapy
  • Hormone therapy
  • Palliative care

EPIDEMIOLOGYMARKETED DRUGSPIPELINE DRUGS
RECENT EVENTS AND ANALYST OPINION
  • Multiple Drugs for Uterine Cancer (March 19, 2021)
  • Bavencio for Uterine Cancer (May 30, 2020)
  • Trodelvy for Uterine Cancer (May 13, 2020)
  • DKN-01 for Uterine Cancer (April 23, 2020)

KEY UPCOMING EVENTS
KEY REGULATORY EVENTS
  • GSK’s Dostarlimab Gets EU Nod For Endometrial Cancer
  • EU Fast-Track Loss For GSK’s Dostarlimab

PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
  • Sorrento Licenses Novel ADC Approach From Mayo Clinic
  • Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal
  • Tyligand Gets Onapristone ER Rights From Context

REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHYAPPENDIX
LIST OF FIGURES
Figure 1: Trends in incident cases of uterine cancer, 2019–28
Figure 2: Overview of pipeline drugs for uterine cancer in the US
Figure 3: Pipeline drugs for uterine cancer, by company
Figure 4: Pipeline drugs for uterine cancer, by drug type
Figure 5: Pipeline drugs for uterine cancer, by classification
Figure 6: Multiple Drugs for Uterine Cancer (March 19, 2021): Phase III - KEYNOTE-775 (w/Pembrolizumab)
Figure 7: Bavencio for Uterine Cancer (May 30, 2020): Phase II - TROPHIMMUN (Gestational Trophoblastic Neoplasias (GTN))
Figure 8: Trodelvy for Uterine Cancer (May 13, 2020): Phase I/II - Epithelial Cancer
Figure 9: DKN-01 for Uterine Cancer (April 23, 2020): Phase II - Gynecologic Malignancies (P204)
Figure 10: Key upcoming events in uterine cancer
Figure 11: Probability of success in the solid tumors pipeline
Figure 12: Clinical trials in uterine cancer
Figure 13: Top 10 drugs for clinical trials in uterine cancer
Figure 14: Top 10 companies for clinical trials in uterine cancer
Figure 15: Trial locations in uterine cancer
Figure 16: Uterine cancer trials status
Figure 17: Uterine cancer trials sponsors by phase
LIST OF TABLES
Table 1: Incident cases of uterine cancer, 2019–28
Table 2: Five-year prevalent cases of uterine cancer, 2019–28
Table 3: Marketed drugs for uterine cancer
Table 4: Pipeline drugs for uterine cancer in the US
Table 5: Multiple Drugs for Uterine Cancer (March 19, 2021)
Table 6: Bavencio for Uterine Cancer (May 30, 2020)
Table 7: Trodelvy for Uterine Cancer (May 13, 2020)
Table 8: DKN-01 for Uterine Cancer (April 23, 2020)
Table 9: Historical global sales, by drug ($m), 2016–20
Table 10: Forecasted global sales, by drug ($m), 2021–25